OPEN Health want to understand the experiences of people living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or acromegaly.

They would like to invite people to take part in a 45-minute interview, conducted either by telephone or video call.
The aim of the interview is to understand the experiences of people with GEP-NETs or acromegaly who recently (within the last six months) transitioned from the Somatuline® syringe [Somatuline® Autogel/ Lanreotide Ipsen®] to the Pharmathen syringe [Lanreotide Advanz Pharma®].
More specifically, they would like to explore:

  • Your experience with switching from the Somatuline® syringe
    to the Pharmathen syringe
  • Your satisfaction and preferences with these syringes.

You can participate if you:

  • Have been diagnosed with GEP-NETs and/or acromegaly
  • Switched from the Somatuline® syringe to the Pharmathen syringe within
    the last six months
  • Have received a minimum of two injections with the Pharmathen syringe.
  • are over 18
  • are in the UK, Italy, Spain, France or the US.

The interviews will be taking place up until May 2024. If you meet the criteria and want to get involved, please contact the research team via email on [email protected] or [email protected].

You will be asked to attend a screening call. This is to explain the process in more detail and make sure you are eligible to participate. You will also be required to complete an informed consent form.

By sharing your perspectives and satisfaction with your treatment, we hope that we can get a better understanding of the challenges of living with GEP-NETs or acromegaly to ultimately develop better ways to help people manage their condition, improve their treatment experiences, and help us provide better care in the future.

Where local regulation allows, you will be compensated for your time spent to complete the interview. Information on participant compensation will be found in the informed consent.